Study investigating the thrombogenicity of SACT in lung cancer
Research type
Research Study
Full title
A study using a new biomarker of clot microstructure, Fractal Dimension (df) to investigate thrombogenicity and the effects of systemic anti cancer therapy (SACT) in lung cancer patients
IRAS ID
279310
Contact name
Simon Noble
Contact email
Sponsor organisation
Aneurin Bevan Health Board
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
The work will be a collaborative effort between Aneurin Bevan University Health Board, Velindre Cancer Centre and the Welsh Centre of Emergency Medicine Research (Swansea University/ABMU). This study will be the first to investigate whether a bio-marker of clot micro-structure formation (gel point and fractal dimension) can quantify how systemic anti cancer treatment in lung cancer effects the way blood clots. We aim to recruit 55 lung cancer patients undergoing systemic anti cancer treatment. This study will build on our previous work which demonstrated that the gel point and fractal dimension biomarker could identify differences in the blood of lung cancer patients compared to controls. Where we could also identify patients with extensive lung cancer compared to a more limited version of the condition. In this new study we hope the results gained will be invaluable in better understanding the thrombotic risks of systemic anti cancer treatment in patients known to be at an increased risk of thrombotic events. This research will potentially lead to the development of a pragmatic risk assessment tool which may then be used to personalize and target treatment to benefit those most at risk, whilst decreasing the complications observed in patients who are not at the highest risk of VTE development.
REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
20/YH/0128
Date of REC Opinion
2 Jun 2020
REC opinion
Further Information Favourable Opinion